DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment.

Study Objectives:

Primary Endpoint
- Dose modification and safety of patients with one DPYD genetic variant (heterozygous DPYD deficiency) when starting at reduced fluoropyrimidine doses.

Secondary Endpoints
- To characterize the continued doses used in heterozygous patients with DPYD variants and their ability to increase or necessity to decrease doses further.

- To characterize the specific grade and nature of fluoropyrimidine-related toxicity in all patient cohorts.

- To determine Time to Progression (TTP) on first fluoropyrimidine treatment for all patients.

- To compare rates of fluoropyrimidine dose reductions and dose intensity between DPYD variant patients and normal control patients.

For further information about clinical trials, please contact us at 732-235-7356.